论文部分内容阅读
目的:观察诺和锐50单次注射在已接受口服降糖药治疗的2型糖尿病血糖及糖化血红蛋白轻度升高的患者中的应用,观察治疗后血糖及糖化血红蛋白达标的情况。方法:选取2014年1月至2016年2月揭阳市慈云医院收治的60例已口服2种或2种以上降糖药治疗而血糖仍轻度升高的2型糖尿病患者,早餐时给予小剂量诺和锐50注射,治疗16周,观察治疗后空腹血糖及糖化血红蛋白达标情况。结果:60例患者在原有口服降糖药治疗的基础上加用小剂量诺和锐50注射,血糖及糖化血红蛋白均有不同程度的下降,血糖及糖化血红蛋白达标率高,低血糖症状发生少。结论:口服2种或2种以上降糖药的2型糖尿病患者,在原治疗基础上加用小剂量诺和锐50注射治疗,可明显提高患者空腹血糖及糖化血红蛋白的达标率。
Objective: To observe the application of Nuoherui 50 single injection in patients with mild type 2 diabetes mellitus and glycosylated hemoglobin who have been treated with oral hypoglycemic agents, and to observe the compliance of glycemia and hemoglobin after treatment. Methods: From January 2014 to February 2016, 60 cases of type 2 diabetic patients who had been treated with 2 or more hypoglycemic agents and the blood glucose was still slightly elevated were treated in Jieyang Ciyun Hospital. Small Novo and sharp dose 50 injection, for 16 weeks, observe the fasting blood glucose and glycosylated hemoglobin compliance after treatment. Results: Sixty patients were treated with Novo-Rehman 50 in small doses on the basis of the original oral hypoglycemic agents. The blood glucose and glycosylated hemoglobin decreased in varying degrees. The rates of blood glucose and glycosylated hemoglobin were high and the symptoms of hypoglycemia were few. Conclusion: Patients with type 2 diabetes who take 2 or more hypoglycemic agents orally can increase the rate of fasting blood glucose and glycosylated hemoglobin in patients with type 2 diabetes mellitus on the basis of the original treatment.